U.S. drugmaker Eli Lilly said on Monday it will offer the higher-dose versions of its popular weight-loss drug Zepbound on ...

Eli Lilly will ship the two highest doses of its popular weight-loss drug Zepbound to cash-paying customers on its website ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg ...

Eli Lilly is unleashing self-pay discounts across the entirety of its obesity portfolio with new price cuts for higher doses ...

Starting July 7, 2025, the two highest doses of Zepbound will be available for a flat price of $499 per month, with shipments ...

Eli Lilly is reducing the price of the highest doses of its popular drug Zepbound for folks who aren't using insurance.

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

The company said the 12.5 milligrams and 15 mg doses of the drug will be available for US$499 per month on the website with shipments to self-paying patients.

Eli Lilly will add 12.5 mg and 15 mg single-dose vials of its weight loss drug Zepbound to its LillyDirect platform starting July 7, completing the full range of approved doses. All vial doses, ...

Eli Lilly and Company (LLY) announced that the highest approved doses of Zepbound —12.5 mg and 15 mg — will soon be available in single-dose vials for $499 per month through LillyDirect's Self Pay ...

Part of the appeal of amylin analogs is the potential to drive weight loss without causing the same level of tolerability problems as GLP-1 receptor agonists. Lilly reported relatively low rates of ...